Clinical Research Directory
Browse clinical research sites, groups, and studies.
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Sponsor: M.D. Anderson Cancer Center
Summary
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
Official title: Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2018-12-18
Completion Date
2027-06-30
Last Updated
2025-10-14
Healthy Volunteers
No
Conditions
Interventions
Computed Tomography
Undergo FDG PET/CT
Computed Tomography
Undergo \[18F\]FTT PET/CT
Fludeoxyglucose F-18
Given IV
Fluorine F 18 Fluorthanatrace
Given IV
Positron Emission Tomography
Undergo FDG PET/CT
Positron Emission Tomography
Undergo \[18F\]FTT PET/CT
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States